Key Studies on Heart Disease, Semaglutide, and TAVR at ACC.25

ACC.25: Exploring Innovations in Cardiovascular Care and AI

The American College of Cardiology (ACC) has released the full schedule of late-breaking clinical trials and clinical research sessions for its annual meeting, ACC.25. These sessions, often the most anticipated, will cover a broad range of topics, including coronary artery disease, semaglutide, artificial intelligence, transcatheter aortic valve replacement (TAVR), heart failure, and percutaneous coronary intervention. The session will be held from March 29-31 at the McCormick Place Convention Center in Chicago, with some sessions available virtually.

Late-breaking clinical trials Session 102 on March 29 will feature three key studies: the Women's Ischemia Trial on outcomes in non-obstructive coronary artery disease, the Phase 3b Stride Trial on the effects of once-weekly subcutaneous semaglutide in people with type 2 diabetes and peripheral artery disease, and the API-CAT Study on extended anticoagulant treatment with reduced versus full-dose apixaban in patients with cancer-associated venous thromboembolism.

On the same date, ACC Late-Breaking Clinical Trials II (Session 104) will present four key studies: the SOUL Randomized Trial on oral semaglutide's effect on cardiovascular events in type 2 diabetes patients with atherosclerotic cardiovascular and/or chronic kidney disease; the efficacy of lorundrostat in uncontrolled hypertension; a deep learning ECG model for coronary revascularization risk stratification in the emergency department; and the use of dapagliflozin in patients undergoing transcatheter aortic valve implantation. Following this, Trial III (Session 105) will present four studies: the RIVAWAR Trial on rivaroxaban vs. warfarin in acute left ventricular thrombus; a Phase 3 study on four-factor prothrombin complex concentrate vs. frozen plasma in bleeding cardiac surgery patients; results from the Reverse-it Trial; and a study on dual-antiplatelet therapy duration after coronary stenting in different bleeding risk populations.

Trials IV (Session 106) on March 30 will present four studies: the MIGHTy-Heart Trial comparing mobile integrated health vs. care coordinators in heart failure patients; a study on fluid intake vs. restriction in chronic heart failure; the Equiox Study on pulse oximeter bias across skin pigments in critically ill adults; and the FAIR-HF2 Trial on morbidity and mortality in iron-deficient chronic heart failure patients. Furthermore, Trials V (Session 107) will feature four studies: the BHF PROTECT-TAVI Trial on cerebral embolic protection in TAVR; outcomes from the Align-AR Clinical Trial on transcatheter valves for pure aortic regurgitation; 5-year outcomes after TAVR or surgical valve replacement in low-risk aortic stenosis patients; and the FLAVOUR II Trial comparing fractional flow reserve vs. intravascular ultrasound-guided PCI strategies.

Later, Trials VI (Session 108) will present four studies: the Triluminate Pivotal Trial on two-year outcomes of transcatheter tricuspid valve repair; 5-year results from the Fractional Flow Reserve vs. Angiography for Multivessel Evaluation 3 Trial; a study comparing clopidogrel vs. aspirin for long-term monotherapy after PCI; and the Alliance for Secondary Prevention after Acute Coronary Syndrome. Featured Clinical Research I (Session 109) on March 30 will present four studies: pre-operative Digifab treatment to prevent AKI in high-risk cardiac bypass patients; the PRAGUE-25 study comparing catheter ablation vs. antiarrhythmic drugs for atrial fibrillation; the Alpaca Phase 2 Trial on small-interfering RNA targeting lipoprotein(a); and the Detect AS Trial on electronic provider notifications for severe aortic stenosis management.

Later, Research II (Session 110) will cover four studies: the Herzcheck study on mobile CMR for heart failure detection in rural areas; the CardiAMP-HF Trial on autologous cell therapy for HFrEF; the Altshock-2 Trial on early intra-aortic balloon pump use in cardiogenic shock; and the Health 360x.ai Registry for AI-driven access to decentralized clinical trials. Research III (Session 111) will feature four studies: the MACRO study on modified cardiac rehabilitation for older adults; survival outcomes after sudden cardiac arrest in young competitive athletes from the United States; the lifetime benefit of controlling modifiable risk factors; and a study on cardiac arrest during long-distance running races from 2010 to 2023.

Featured Clinical Research IV (Session 112) on March 31 will present four studies: the SUMMIT Trial on tripeptide for heart failure with preserved ejection fraction, obesity, and chronic kidney disease; the EKSTROM Trial on colchicine and coronary atherosclerosis progression; the DECODE-CKD Trial on dapagliflozin’s effects on cardiac structure in chronic kidney disease; and a Phase 2 trial on solbinsiran's effects on cardiovascular biomarkers in mixed dyslipidemia. Clinical and Investigative Horizons I (Session 402) will present five studies: a Phase Ib/2a study on Tn-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy; the Confirm2 study on AI QCT coronary plaque features, with greater effects in females; the impact of berberine hydrochloride on visceral and liver fat; AI’s role in enabling novice echocardiography; and results from the ZENITH Phase 3 trial on sotatercept in high-risk pulmonary arterial hypertension patients.

Featured Clinical Research V (Session 113) will present four studies: a sub-analysis of the Early TAVR Trial on aortic valve replacement timing; the ARISE-ARMYDA 7 trial on antithrombotic pathways in acute MI with large thrombus; a Phase 2b trial on azd0780, a PCSK9 inhibitor for hypercholesterolemia; and a multicenter study on the 0/1-hour chest pain assessment algorithm in Asian emergency departments. Another session, Late-Breaking Clinical Trial Deep Dive I (Session 418), will provide further insights from key clinical trials presented at ACC.25 and their implications for patient care.

ACC Clinical and Investigative Horizons II (Session 434) will present five studies: a Phase 2 trial on SHR-1918 for hyperlipidemia; a post-hoc analysis of the Esprit Trial on intensive blood pressure control in frail patients; the ECLIPSE Trial on intravascular imaging in PCI for calcified lesions; a study on AI-assisted cardiologist reporting of severe aortic stenosis; and a biomarker analysis from the EARLY TAVR Trial on asymptomatic severe aortic stenosis. Late-Breaking Clinical Trial Deep Dive II (Session 450) will offer additional insights from key clinical trials presented at ACC.25, focusing on their implications for patient care. Overall, ACC.25 promises to be a pivotal event, showcasing groundbreaking research across a wide range of cardiovascular topics. Attendees can expect to gain valuable insights into the latest clinical advancements, shaping the future of patient care.

Editor's Note:

The American College of Cardiology's ACC.25 conference is set to unveil the latest breakthroughs in cardiovascular medicine, featuring a wide array of late-breaking clinical trials and cutting-edge research. From advances in coronary artery disease and heart failure to the role of artificial intelligence and innovative therapies, this year's sessions promise to provide vital insights that will influence the future of cardiovascular care. 

Skoobuzz hopes that these sessions will spark meaningful discussions and collaborations, fostering a deeper understanding of the evolving landscape of cardiovascular care.